Posts Archive

EMN 28 European Myeloma Network EMN28/68284528MMY3005 NCT05257083: Phase 3 : A Study of Daratumumab, Bortezomib, Lenalidomide and...

NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple...

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma iMMagine-1 NCT05396885: Phase 2: Study of...

NCT05393804: Phase 2: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell...

GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in...

NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell...

NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell...

NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05219721:...

NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel NCT05201781: Phase 4: A...

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma The...

NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma PHE885 CAR-T Therapy in...

(OriCAR-017) CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS) NCT05016778: Phase 1: A...

NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma This research study involves the study of TriPRIL CAR T Cells for treating...

FUMANBA-1 NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory...

NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy The aim of this...

bb2121 Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7) KarMMa-7 Relapsed & Refractory Multiple...

CARTITUDE-5 Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against...

NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After...

NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM) NCT04960579: Phase 1:...